Evidence map›Paper›PMID 24622963›Full record

ArticleRadiation and environmental biophysics2014

DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.

Melvin Lee Kiang Chua, Simon Horn, Navita Somaiah, Sue Davies, Lone Gothard, Roger A'Hern, John Yarnold, Kai Rothkamm

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Radiation and environmental biophysics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02780375 (Feasibility Study Testing Multi-panel Coding and Non-coding Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects in Radiation Therapy Patients), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02780375 completednot on this mapstarted 2016, after this paper: background citation

Feasibility Study Testing Multi-panel Coding and Non-coding Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects in Radiation Therapy Patients

TypeobservationalSponsorInstitute of Cancer Research, United KingdomRan2016 to 2018Enrolled20ConditionsCancerArmsBlood donation during radiotherapy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Clinical outcomes of prexasertib monotherapy in recurrentJournal for immunotherapy of cancer · 2020
    Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Iranian journal of basic medical sciences · 2018
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. EPRBioDose 2013: EPR applications and biological dosimetry.Radiation and environmental biophysics · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Melvin Lee Kiang ChuaPublic Health England, Centre for Radiation, Chemical and Environmental Hazards, Chilton, OX11 0RQ, UK.
Simon Horn
Navita Somaiah
Sue Davies
Lone Gothard
Roger A'Hern
John Yarnold
Kai Rothkamm
Royal Marsden NHS Foundation Trust · GBPublic Health England · GBInstitute of Cancer Research · GB

Funding

Cancer Research UK 10588Cancer Research UK 15955Medical Research Council G9600656
6 · The paper itself

Abstract

This study aimed to test whether induction of apoptosis following ex vivo X-irradiation of unstimulated blood lymphocytes correlated with clinical radiosensitivity and DNA double-strand break (DSB) repair in breast radiotherapy patients and healthy volunteers. Using small molecule inhibitors, the relationship between DSB repair and radiation-induced apoptosis was examined. Sixteen breast cancer patients with minimal (controls, n = 8) or extremely marked late radiation-induced change (cases, n = 8) and eight healthy volunteers were selected. DSBs were quantified by γH2AX/53BP1 immunofluorescence, and apoptosis was measured using a fluorogenic inhibitor of caspases assay. Mean γH2AX/53BP1 focus levels 24 h after exposure to 4 Gy were higher in cases (12.7 foci per cell) than in controls (10.3 foci per cell, p = 0.002). In contrast, the mean apoptotic fraction 48 h after 8 Gy was comparable, 37.2 % in cases and 34.7 % in controls (p = 0.442). Residual focus and apoptosis levels were not correlated within individuals (Spearman's R = -0.0059, p = 0.785). However, cells treated with DNA-PK inhibitor Nu7441 had higher focus and apoptosis levels 48 h after 1 Gy compared to mock-treated cells, suggesting that apoptosis induction following irradiation is modulated by DSB repair. This effect required functional ATM since cells treated simultaneously with Nu7441 and the ATM inhibitor Ku55933 were resistant to apoptosis despite high levels of residual foci. One clinical case displayed an impaired DNA-PK-dependent end-joining cellular phenotype. In summary, clinical radiosensitivity may be associated with impaired DSB repair in some patients. Although pharmaceutical inhibition of ATM and DNA-PK affected apoptosis induction and DSB repair, no association was observed between apoptosis and residual focus levels in patients and volunteers.

Indexed as

AdultAgedApoptosisAtaxia Telangiectasia Mutated ProteinsBreast NeoplasmsCase-Control StudiesChromonesDNA-Activated Protein KinaseDNA Breaks, Double-StrandedDNA RepairEnzyme ActivationFemaleHistonesHumansIntracellular Signaling Peptides and ProteinsLymphocytes2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-oneAtaxia Telangiectasia Mutated ProteinsChromonesDNA-Activated Protein KinaseH2AX protein, humanHistonesIntracellular Signaling Peptides and ProteinsMorpholinesNuclear ProteinsPRKDC protein, humanProtein Kinase InhibitorsPyronesTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1

Identifiers

PMID24622963
OpenAlexW1975425968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.